Last reviewed · How we verify
chlorexidine
chlorexidine is a Small molecule drug developed by Universidade Federal do Ceara. It is currently in Phase 2 development.
Chlorhexidine is an oral hygiene intervention used to prevent conditions such as Ventilator Associated Pneumonia. It is also used in classical training settings, but its primary use is in oral hygiene.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | chlorexidine |
|---|---|
| Sponsor | Universidade Federal do Ceara |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of a Xanthan-based Chlorhexidine Gel in the Treatment of Peri-implant Mucositis (NA)
- Evaluation of Chlorhexidine Gel Associated with Photodynamic Therapy in the Treatment of Chronic Periodontitis in Type 2 Diabetics (NA)
- Daily Chlorexidine Bath for Health Care Associated Infection Prevention (PHASE3)
- Effect of Virtual Reality Glasses Application on Surgical Fear and Anxiety (NA)
- Surgical Protocol for Peri-Implantitis Treatment-4 (NA)
- Digital Radiography in Detection of Recurrent Caries Underneath Chlorhexidine Containing Adhesive Versus Conventional Adhesive After One Year Follow up: Randomized Clinical Trial (NA)
- Effectiveness of Preoperative Surgical Scrubbing Using Clorhexidine Digluconate and Parachlorometaxylenol (ECP) (NA)
- Hexetidine and Chlorobutanol for Lesions Due to Prostheses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chlorexidine CI brief — competitive landscape report
- chlorexidine updates RSS · CI watch RSS
- Universidade Federal do Ceara portfolio CI
Frequently asked questions about chlorexidine
What is chlorexidine?
Who makes chlorexidine?
What development phase is chlorexidine in?
Related
- Manufacturer: Universidade Federal do Ceara — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing